Literature DB >> 26027432

The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.

Brenda Auffinger1, Drew Spencer, Peter Pytel, Atique U Ahmed, Maciej S Lesniak.   

Abstract

Glioma stem cells (GSCs) constitute a slow-dividing, small population within a heterogeneous glioblastoma. They are able to self-renew, recapitulate a whole tumor, and differentiate into other specific glioblastoma multiforme (GBM) subpopulations. Therefore, they have been held responsible for malignant relapse after primary standard therapy and the poor prognosis of recurrent GBM. The failure of current therapies to eliminate specific GSC subpopulations has been considered a major factor contributing to the inevitable recurrence in GBM patients after treatment. Here, we discuss the molecular mechanisms of chemoresistance of GSCs and the reasons why complete eradication of GSCs is so difficult to achieve. We will also describe the targeted therapies currently available for GSCs and possible mechanisms to overcome such chemoresistance and avoid therapeutic relapse.

Entities:  

Keywords:  chemoresistance; glioma stem cells; malignant glioma; mechanisms; plasticity; recurrence

Mesh:

Substances:

Year:  2015        PMID: 26027432      PMCID: PMC4830899          DOI: 10.1586/14737175.2015.1051968

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  111 in total

1.  The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Authors:  Yasuo Imai; Mayumi Yoshimori; Kazunori Fukuda; Hidetsugu Yamagishi; Yoshihiko Ueda
Journal:  Oncol Rep       Date:  2012-03-15       Impact factor: 3.906

2.  O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Authors:  Mirjam Hermisson; Andrea Klumpp; Wolfgang Wick; Jörg Wischhusen; Georg Nagel; Wynand Roos; Bernd Kaina; Michael Weller
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

3.  Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.

Authors:  S B Wharton; U McNelis; H S Bell; I R Whittle
Journal:  Neuropathol Appl Neurobiol       Date:  2000-12       Impact factor: 8.090

4.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

5.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

6.  A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.

Authors:  Lula Rosso; Cathryn S Brock; James M Gallo; Azeem Saleem; Patricia M Price; Federico E Turkheimer; Eric O Aboagye
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.

Authors:  Zhe Bao Wu; Chao Qiu; An Li Zhang; Lin Cai; Shao Jian Lin; Yu Yao; Qi Sheng Tang; Ming Xu; Wei Hua; Yi Wei Chu; Ying Mao; Jian Hong Zhu; Jianqing Xu; Liang Fu Zhou
Journal:  J Immunol Res       Date:  2014-07-09       Impact factor: 4.818

8.  Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.

Authors:  Anna Golebiewska; Sébastien Bougnaud; Daniel Stieber; Nicolaas H C Brons; Laurent Vallar; Frank Hertel; Barbara Klink; Evelin Schröck; Rolf Bjerkvig; Simone P Niclou
Journal:  Brain       Date:  2013-03-04       Impact factor: 13.501

9.  miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Authors:  Joachim Silber; Daniel A Lim; Claudia Petritsch; Anders I Persson; Alika K Maunakea; Mamie Yu; Scott R Vandenberg; David G Ginzinger; C David James; Joseph F Costello; Gabriele Bergers; William A Weiss; Arturo Alvarez-Buylla; J Graeme Hodgson
Journal:  BMC Med       Date:  2008-06-24       Impact factor: 8.775

Review 10.  Adoptive cell therapies for glioblastoma.

Authors:  Kevin Bielamowicz; Shumaila Khawja; Nabil Ahmed
Journal:  Front Oncol       Date:  2013-11-11       Impact factor: 6.244

View more
  91 in total

1.  Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles.

Authors:  Gabriela D A Guardia; Bruna R Correa; Patricia Rosa Araujo; Mei Qiao; Suzanne Burns; Luiz O F Penalva; Pedro A F Galante
Journal:  NPJ Genom Med       Date:  2020-01-16       Impact factor: 8.617

2.  The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.

Authors:  Yan Hu; Meilian Zhang; Ningyu Tian; Dengke Li; Fan Wu; Peishan Hu; Zhixing Wang; Liping Wang; Wei Hao; Jingting Kang; Bin Yin; Zhi Zheng; Tao Jiang; Jiangang Yuan; Boqin Qiang; Wei Han; Xiaozhong Peng
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

3.  Profiling of microRNAs modulating cytomegalovirus infection in astrocytoma patients.

Authors:  Ravindra Pramod Deshpande; Manas Panigrahi; Chandrasekhar Y B V K; Phanithi Prakash Babu
Journal:  Neurol Sci       Date:  2018-08-08       Impact factor: 3.307

4.  SOX2 immunity and tissue resident memory in children and young adults with glioma.

Authors:  Juan C Vasquez; Anita Huttner; Lin Zhang; Asher Marks; Amy Chan; Joachim M Baehring; Kristopher T Kahle; Kavita M Dhodapkar
Journal:  J Neurooncol       Date:  2017-06-15       Impact factor: 4.130

5.  Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Authors:  Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

6.  Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.

Authors:  Junseong Park; Jin-Kyoung Shim; Joon Hee Kang; Junjeong Choi; Jong Hee Chang; Soo-Youl Kim; Seok-Gu Kang
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

7.  Current Progress of Phytomedicine in Glioblastoma Therapy.

Authors:  Fahad Hassan Shah; Saad Salman; Jawaria Idrees; Fariha Idrees; Syed Turab Ali Shah; Abid Ali Khan; Bashir Ahmad
Journal:  Curr Med Sci       Date:  2021-01-11

Review 8.  Translational gap in ongoing clinical trials for glioma.

Authors:  Alecia Florence Guishard; Juan Sebastian Yakisich; Neelam Azad; Anand Krishnan V Iyer
Journal:  J Clin Neurosci       Date:  2017-10-21       Impact factor: 1.961

Review 9.  Novel ablation methods for treatment of gliomas.

Authors:  Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus
Journal:  J Neurosci Methods       Date:  2020-02-14       Impact factor: 2.390

10.  Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.

Authors:  Ulf D Kahlert; Abigail K Suwala; Katharina Koch; Manabu Natsumeda; Brent A Orr; Masanori Hayashi; Jarek Maciaczyk; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2015-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.